Lab Stakeholders Still Oppose FDA’s Multivariate Assay Policy
This article was originally published in The Gray Sheet
Executive Summary
Laboratories are urging FDA to once again rework, if not abandon, its proposal to actively regulate certain lab-developed tests, while diagnostics companies are split on the issue